Format
Sort by
Items per page

Send to

Choose Destination

Best matches for MELPHALAN/PD:

Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Cho YK et al. Clin Pharmacol Ther. (2017)

Oral melphalan for the treatment of relapsed canine lymphoma. Mastromauro ML et al. Vet Comp Oncol. (2018)

Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. Buitrago E et al. J Ocul Pharmacol Ther. (2016)

Search results

Items: 1 to 20 of 5050

1.

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Ann Hematol. 2019 Sep;98(9):2233-2235. doi: 10.1007/s00277-019-03734-7. Epub 2019 Jun 26. No abstract available.

PMID:
31243571
2.

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.

Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A, Eigentler T, Syha R, Grözinger G.

Cancer Imaging. 2019 May 30;19(1):31. doi: 10.1186/s40644-019-0218-4.

3.

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E.

Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20.

PMID:
31111177
4.

Surface-Modified Melphalan Nanoparticles for Intravitreal Chemotherapy of Retinoblastoma.

Sims LB, Tyo KM, Stocke S, Mahmoud MY, Ramasubramanian A, Steinbach-Rankins JM.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1696-1705. doi: 10.1167/iovs.18-26251.

PMID:
31009525
5.

Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).

Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.

Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1.

PMID:
30937622
6.

Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.

Chung A, Liedtke M.

Best Pract Res Clin Haematol. 2019 Mar;32(1):54-64. doi: 10.1016/j.beha.2019.02.003. Epub 2019 Feb 8. Review.

PMID:
30927976
7.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
8.

Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.

Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, Richmond A.

Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):954-964. doi: 10.1167/iovs.18-25346.

9.

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma.

Blanes M, Lorenzo JI, Ribas P, Jiménez A, González JD, Cejalvo MJ, Solano C, Alegre A, de la Rubia J.

Ann Hematol. 2019 Aug;98(8):2013-2015. doi: 10.1007/s00277-019-03663-5. Epub 2019 Mar 16. No abstract available.

PMID:
30879095
10.

Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.

Kroon HM, Coventry BJ, Henderson MA, Barbour A, Serpell J, Smithers BM, Thompson JF.

Eur J Surg Oncol. 2019 May;45(5):832-837. doi: 10.1016/j.ejso.2019.02.026. Epub 2019 Feb 27.

PMID:
30867095
11.

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.

Sun W, Li L, Du Z, Quan Z, Yuan M, Cheng H, Gao Y, Luo C, Wu X.

Oncol Rep. 2019 May;41(5):2689-2702. doi: 10.3892/or.2019.7054. Epub 2019 Mar 7.

12.

High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).

Fujino H, Ishida H, Iguchi A, Onuma M, Kato K, Shimizu M, Yasui M, Fujisaki H, Hamamoto K, Washio K, Sakaguchi H, Miyashita E, Osugi Y, Nakagami-Yamaguchi E, Hayakawa A, Sato A, Takahashi Y, Horibe K.

Int J Hematol. 2019 May;109(5):578-583. doi: 10.1007/s12185-019-02627-9. Epub 2019 Mar 12.

PMID:
30864117
13.

Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.

Xue K, Ren H, Meng F, Zhang R, Qian J.

BMC Ophthalmol. 2019 Feb 26;19(1):61. doi: 10.1186/s12886-019-1059-4.

14.

[Autologous peripheral blood stem cell transplantation for POEMS syndrome].

Liao LS, Zheng ZH, Qu S, Wei TN, Xie Y, Lin Y, Chen BY, Chen WM.

Zhonghua Nei Ke Za Zhi. 2019 Mar 1;58(3):209-212. doi: 10.3760/cma.j.issn.0578-1426.2019.03.011. Chinese.

PMID:
30803180
15.

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.

Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei LF, Kapiteijn E, de Leede EM, Martini CH, van der Meer RW, Tijl FGJ, Vahrmeijer AL.

Cardiovasc Intervent Radiol. 2019 Jun;42(6):841-852. doi: 10.1007/s00270-019-02177-x. Epub 2019 Feb 14.

16.

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Hoshino T, Takada S, Hatsumi N, Sakura T.

Int J Hematol. 2019 Apr;109(4):463-469. doi: 10.1007/s12185-019-02610-4. Epub 2019 Feb 8.

PMID:
30734904
17.

Intra-Arterial Chemotherapy for Retinoblastoma: 8-Year Experience from a Tertiary Referral Institute in Thailand.

Rojanaporn D, Chanthanaphak E, Boonyaopas R, Sujirakul T, Hongeng S, Ayudhaya SSN.

Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):211-217. doi: 10.22608/APO.2018294. Epub 2019 Feb 4.

PMID:
30714357
18.

What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?

Zhao H, Huang XF, Gao XM, Cai H, Zhang L, Feng J, Cao XX, Zhou DB, Li J.

Leukemia. 2019 Apr;33(4):1023-1029. doi: 10.1038/s41375-019-0391-2. Epub 2019 Jan 30.

19.

Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.

Smallwood K, Tanis JB, Grant IA, Blackwood L, Killick DR, Amores-Fuster I, Elliott J, Mas A, Harper A, Marrington M, Finotello R.

Vet Comp Oncol. 2019 Jun;17(2):165-173. doi: 10.1111/vco.12457. Epub 2019 Feb 13.

PMID:
30666777
20.

Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study.

Stenzel E, Göricke S, Temming P, Biewald E, Zülow S, Göbel J, Wanke I, Umutlu L, Kleinschnitz C, Bornfeld N, Forsting M, Radbruch A, Mönninghoff C.

Neuroradiology. 2019 Mar;61(3):351-357. doi: 10.1007/s00234-019-02153-9. Epub 2019 Jan 14.

PMID:
30643921

Supplemental Content

Loading ...
Support Center